Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and parkinson patients

Current Alzheimer Research

Volumn 7, Issue 6, 2010, Pages 549-555

  Ullrich, C ^a   Mlekusch, R ^a   Kuschnig, A ^b   Marksteiner, J ^c   Humpel, C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c Landeskrankenhaus Rankweil ^*  (Austria)

Author keywords

Blood cells; Diagnosis; Mild cognitive impairment; PBMC

Indexed keywords

CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MEMANTINE; PROTEASOME; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE;

AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MALE; MILD COGNITIVE IMPAIRMENT; NONHUMAN; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; ANIMALS; BLOOD CELLS; CHYMOTRYPSIN; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; STATISTICS, NONPARAMETRIC; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES;

EID: 78549274350     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510792231766     Document Type: Article

References (39)

1. Grillari J, Katinger H, Voglaue R. Aging and the ubiquitinome: Traditional and non-traditional functions of ubiqutin in aging cells and tissues. Exp Geront 41: 1067-1079 (2006).
2. Pallares-Trujillo J, Lopez-Soriano EJ, Argiles JM. The involvement of the ubiquitin system in Alzheimeŕs disease. Int J Mol Med 2: 3-15 (1998).
3. De Vrij FM, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 74: 249-270 (2004).
4. Glickman MH and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428 (2002).
5. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinsons disease. Nature 395: 451-452 (1998).
6. Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 66: 7-19 (2006).
7. Hegde AN, Upadhya SC. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 30: 587-595 (2007).
8. Martinez-Vicente M, Sovak G, Cuervo AM. Protein degradation and aging. Exp Geront 40: 622-633 (2005).
9. Pickart CM. Mechanisms underlying ubiquitiniation. Ann Rev Biochem 70: 503-533 (2001).
10. Hochstrasser M. Ubiquitin-dependent protein degradation. Ann Rev Genet 30: 405-439 (1996).
11. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays 22: 442-451 (2000).
12. Wang GP, Khatoon S, Iqbal K, Grundke-Iqbal I. Brain ubiquitin is markedly elevated in Alzheimer disease. Brain Res 566: 146-151(1991).
13. Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res 639: 1-7 (1994).
14. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439 (2000).
15. Ponnappan U. Ubiquitin-proteasome pathway is compromised in CD45RO+ and CD45RA+ T lymphocyte subsets during aging. Exp Gerontol 37: 359 (2002).
16. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68: 1902-1908 (2007).
17. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, et al. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell 12: 553-563 (2003).
18. Marksteiner J, Kemmler G, Weiss EM, Knauss G, Ullrich C, Mechteriakov S, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimers disease. Neurobiol Aging [Epub ahead of print] (2009).
19. Marksteiner J, Humpel C. Glycogen-synthase kinase-3 beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. Exp Gerontol 44: 370-1 (2009).
20. Marksteiner J, Humpel C. Beta-amyloid expression, release and extracellular deposition in aged rat brain slices. Mol Psychiatry 1-14 (2008).
21. Klimaschewski L, Hausott B, Ingorokva S, Pfaller K. Constitutively expressed catalytic proteasomal subunits are up-regulated during neuronal differentiation and required for axon initiation, elongation and maintenance. J Neurochem 96: 1708-1717 (2006).
22. Blandini F, Sinforiani E, Pacchetti C, Samuele A, Bazzini E, Zanganglia R, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66: 529-534 (2006).
23. Schmitt HP. Protein ubiquitination, degradation and the proteasome in neurodegerative disorders: no clear evidence for a significant pathogenetic role of proteasome failure in Alzheimers disease and related disorders. Med Hypotheses 67: 311-317 (2006).
24. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 84: 3033-3036 (1987).
25. Master E, Chan SL, Ali-Khan Z. Ubiquitin (Ub) interacts non-covalently with Alzheimer amyloid precursor protein (betaPP): isolation of Ub-betaPP conjugates from brain extracts. Neuroreport 8: 2781-2786 (1997).
26. López Salon M, Morelli L, Castaño EM, Soto EF, Pasquini JM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 62: 302-310 (2000).
27. Bergman M, Salman H, Beloosesky Y, Djaldetti M, Bessler H. Are peripheral blood cells from patients with Alzheimer disease more sensitive to apoptotic stimuli? Alzheimer Dis Assoc Disord 16: 156-160 (2002).
28. Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schröder J, et al. Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr Alzheimer Res 5: 358-366 (2008).
29. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev 65: 173-176 (2007).
30. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, et al. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflam 5: 51 (2008).
31. Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinsońs disease. Biochim Biophys Acta 1792: 664-675 (2009).
32. McNaught KS, Perl DP, Brownell A, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56: 149-162 (2004).
33. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nature Rev 10: 319-331 (2009).
34. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 67: 425-479 (1998).
35. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899 (2003).
36. Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med 256: 224-234 (2004).
37. Blennow K. CSF biomarkers for Alzheimeŕs disease: use in early diagnosis and evaluation of drug treatment. Exp Rev Mol Diagn 5: 661-672 (2005).
38. Humpel C, Marksteiner J. Peripheral biomarkers in dementia and Alzheimers disease. In: "The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes, Volume III: Metabolic and Peripheral Biomarkers", Michael S. Ritsner Ed., Springer; ISBN: 978-1-4020-9837-6 (2009).
39. Ray S, Britschgi M, Herbert C, Takedu-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362 (2007).